56 Participants Needed

Selinexor for Sarcoma

AR
Overseen ByAlbiruni Razak, M.D.
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: University Health Network, Toronto
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 2 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a phase 1, open-label, single centre study of investigational drug selinexor in participants with soft tissue sarcomas that cannot be treated with standard therapies. Selinexor has been given to 3111 participants with cancer to date including 142 sarcoma patients. Early findings have shown that selinexor is effective in multiple cancer types. The current study is being done to test low doses and different dosing schedules of selinexor to find out if it reduces the side effects without compromising the benefits.This study has 2 groups or Arms: Arm A and Arm B.Arm A (Dose escalation Arm): Participants will receive selinexor by mouth 4 days a week to find out the safety, tolerability and anti-tumor effect of low doses of Selinexor in participants with advanced or metastatic malignant peripheral nerve sheath tumors (MPNST), endometrial stromal sarcomas (ESS) and leiomyosarcoma (LMS). Participants will continue on study until disease progression or unacceptable side effects. Up to 36 participants will be enrolled in this Arm.Arm B: Participants with any soft tissue sarcoma subtypes will be enrolled in this Arm. They will receive flat doses of Selinexor by mouth once weekly, 3 times a day. Safety and tolerability will be assessed in this Arm. Up to 20 participants will be enrolled and they will continue to receive selinexor until disease progression or unacceptable side effects.Cancer is the uncontrolled growth of human cells. One of the ways cancers cells continue to grow is by getting rid of proteins called "tumor suppressor proteins" that would normally cause cancer cells to die. The study drug works by trapping "tumor suppressor proteins" within the cell, causing the cancer cells to die or stop growing.The study comprises 3 periods: Screening (up to 28 days), Study Drug (until disease progression), and Survival Follow-Up (once every 3 months). Procedures for research purposes only will include blood collection and study questionnaire.

Who Is on the Research Team?

Dr. Albiruni Razak | Bras DDP

Albiruni Razak, MD

Principal Investigator

Princess Margaret Cancer Centre

Are You a Good Fit for This Trial?

This trial is for adults over 18 with advanced soft tissue sarcomas that can't be treated with standard therapies. Participants must have certain blood counts, organ functions within specific ranges, and not be pregnant or breastfeeding. They should also agree to use contraception and not have had recent cancer treatments or major surgeries.

Inclusion Criteria

You must have a measurable disease according to the RECIST 1.1 guidelines.
My soft tissue sarcoma type qualifies for Arm B of the study.
I can swallow pills.
See 14 more

Exclusion Criteria

I have not had major surgery in the last 4 weeks.
The doctor thinks you are very underweight for your height.
I have previously been treated with selinexor or a similar drug.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

Up to 4 weeks

Treatment

Participants receive Selinexor orally in two different dosing schedules: Arm A with metronomic dosing and Arm B with split dosing, until disease progression or unacceptable side effects.

2 to 12 months

Follow-up

Participants are monitored for safety and effectiveness after treatment completion, with follow-up every 3 months.

Up to 2 years

What Are the Treatments Tested in This Trial?

Interventions

  • Selinexor
Trial Overview The study tests different low doses and schedules of Selinexor taken orally to see if they're effective but cause fewer side effects in sarcoma patients. Arm A will test the drug four days a week on specific sarcoma types, while Arm B involves any soft tissue sarcoma subtype taking it once weekly.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: Split dosingExperimental Treatment1 Intervention
Group II: Metronomic dosingExperimental Treatment1 Intervention

Selinexor is already approved in United States, Canada for the following indications:

🇺🇸
Approved in United States as Xpovio for:
🇨🇦
Approved in Canada as Xpovio for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

University Health Network, Toronto

Lead Sponsor

Trials
1,555
Recruited
526,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security